Get the Stockscreener App
26.30
1.54%
0.40
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $26.30, with a volume of 51.91M.
It is up +1.54% in the last 24 hours and down -1.28% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$25.90
Open:
$25.89
24h Volume:
51.91M
Relative Volume:
1.31
Market Cap:
$149.04B
Revenue:
$63.63B
Net Income/Loss:
$8.03B
P/E Ratio:
18.65
EPS:
1.41
Net Cash Flow:
$8.23B
1W Performance:
+3.02%
1M Performance:
-1.28%
6M Performance:
-9.40%
1Y Performance:
-4.95%
1-Day Range:
$25.84
$26.57
1-Week Range:
$25.42
$26.57
52-Week Range:
$24.48
$31.54
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
26.30 | 149.04B | 63.63B | 8.03B | 8.23B | 1.41 |
|
LLY
Lilly Eli Co
|
873.68 | 830.35B | 45.04B | 10.59B | 414.30M | 11.71 |
|
NVO
Novo Nordisk Adr
|
88.08 | 390.99B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
ABBV
Abbvie Inc
|
202.08 | 356.74B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
162.30 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
MRK
Merck Co Inc
|
89.50 | 251.88B | 64.17B | 17.12B | 14.84B | 6.7297 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Pfizer Cuts Last AAV Gene Therapy Program By Taking Beqvez Off The Market - News & Insights
Pfizer Jettisons FDA-Approved Hemophilia B Gene Therapy Beqvez - CGTLive™
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight - GlobeNewswire Inc.
Pfizer Discontinues Hemophilia Gene Therapy Beqvez As Interest Wanes - Yahoo Finance
Pfizer shelves haemophilia gene therapy Beqvez amid low demand - Yahoo Finance
Pfizer: Investors Won't Stick Around Forever (NYSE:PFE) - Seeking Alpha
Ozempic, Wegovy shortage resolved; Pfizer CEO is PhRMA’s new chair - BioPharma Dive
Pfizer stops selling hemophilia gene therapy, citing weak demand - BioPharma Dive
An awkward moment for Pfizer’s Bourla in Washington - STAT
Topical Drug Delivery Market Booming Innovations & Forecast 2032 with Johnson & Johnson, Pfizer Inc., GSK plc, - EIN News
Is Pfizer Inc. (PFE) the Best Non-Tech Stock to Buy Now for Long Term? - Insider Monkey
Capital Advisory Group Advisory Services LLC Makes New $292,000 Investment in Pfizer Inc. (NYSE:PFE) - MarketBeat
Bradley Foster & Sargent Inc. CT Purchases 139,215 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
Health Rounds: Swabs as good as unpleasant speculum exam for detecting cancer-causing HPV - Marketscreener.com
Pfizer Inc. (NYSE:PFE) is WP Advisors LLC's 5th Largest Position - MarketBeat
Pfizer Inc. (NYSE:PFE) Shares Purchased by Kentucky Retirement Systems Insurance Trust Fund - MarketBeat
Compass Capital Corp MA ADV Buys Shares of 49,457 Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer stops commercialization of hemophilia gene therapy Beqvez - Reuters
ING Groep NV Boosts Stock Holdings in Pfizer Inc. (NYSE:PFE) - MarketBeat
Ieq Capital LLC Purchases 40,117 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer Inc. (NYSE:PFE) Shares Sold by Bryn Mawr Capital Management LLC - MarketBeat
#Pfizer has announced a strategic marketing and supply agreement with Mylan Pharmaceuticals. The deal aims to bolster distribution and sales of its two well-known brands, Ativan and Pacitane, in India. #Pharmaceuticals - linkedin
Sanctuary Advisors LLC Cuts Holdings in Pfizer Inc. (NYSE:PFE) - MarketBeat
Ataxia Market Future Business Opportunities 2025-2032 | Pfizer, Inc., CRISPR Therapeutics, Acorda Therapeutics - openPR
Principal Financial Group Inc. Has $169.90 Million Stock Holdings in Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer (NYSE:PFE) Trading Up 0%Still a Buy? - MarketBeat
Pfizer says it will end global development of hemophilia gene therapy Beqvez - TradingView
Pfizer nixes Roche-partnered hemophilia drug (PFE:NYSE) - Seeking Alpha
Pfizer says it will end global development of gene therapy Beqvez, Nikkei reports -February 20, 2025 at 02:58 pm EST - Marketscreener.com
Pfizer halts work on hemophilia gene therapy - Nikkei Asia
Pfizer (NYSE:PFE) Shares Up 0.1%Here's What Happened - MarketBeat
Pfizer's Big Game Ad Wins LinkedIn Member Poll - Pfizer
What's Driving the Market Sentiment Around Pfizer? - Benzinga
U.S. Diabetic Neuropathy Market to Witness Stunning Growth with Eli Lilly & Company, Johnson & Johnson - EIN News
Boston Financial Mangement LLC Increases Stake in Pfizer Inc. (NYSE:PFE) - MarketBeat
14,772 Shares in Pfizer Inc. (NYSE:PFE) Purchased by Advyzon Investment Management LLC - MarketBeat
First Bank & Trust Has $1.76 Million Holdings in Pfizer Inc. (NYSE:PFE) - MarketBeat
Davidson Investment Advisors Sells 100,344 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
Handelsbanken Fonder AB Has $64.14 Million Stake in Pfizer Inc. (NYSE:PFE) - MarketBeat
Private Wealth Partners LLC Raises Position in Pfizer Inc. (NYSE:PFE) - MarketBeat
Cumberland Partners Ltd Acquires Shares of 76,600 Pfizer Inc. (NYSE:PFE) - MarketBeat
Private Advisor Group LLC Reduces Stock Holdings in Pfizer Inc. (NYSE:PFE) - MarketBeat
Global Retirement Partners LLC Sells 24,744 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
Vasopressin Market Is Booming Worldwide 2025-2032 | Par - openPR
Callahan Advisors LLC Purchases 69,155 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board of Directors for Breach of Fiduciary Duties (PFE) - TradingView
Trump to meet pharma leaders as they seek drug policy changes - Reuters
Pfizer (NYSE:PFE) Stock Price Down 0.6%Here's Why - MarketBeat
Pfizer (NYSE:PFE) Trading Up 0.9%Still a Buy? - MarketBeat
Pfizer (NYSE:PFE) Shares Up 0.1% on Insider Buying Activity - MarketBeat
TigerOak Management L.L.C. Purchases New Holdings in Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.07%
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):